Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.

Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA.

J Clin Oncol. 2014 Feb 10;32(5):438-43. doi: 10.1200/JCO.2013.52.4645. Epub 2014 Jan 6.

PMID:
24395857
[PubMed - indexed for MEDLINE]
2.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.

PMID:
23104323
[PubMed - indexed for MEDLINE]
Free Article
3.

Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.

Konno R, Tamura S, Dobbelaere K, Yoshikawa H.

Cancer Sci. 2011 Apr;102(4):877-82. doi: 10.1111/j.1349-7006.2011.01878.x. Epub 2011 Feb 17.

PMID:
21251162
[PubMed - indexed for MEDLINE]
4.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
[PubMed - indexed for MEDLINE]
Free Article
5.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

PMID:
19789295
[PubMed - indexed for MEDLINE]
6.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
[PubMed - indexed for MEDLINE]
7.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

PMID:
24148310
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).

Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM.

BMC Cancer. 2013 Jun 19;13:296. doi: 10.1186/1471-2407-13-296.

PMID:
23777549
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.

Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK.

J Natl Cancer Inst. 2014 Mar;106(3):djt460. doi: 10.1093/jnci/djt460. Epub 2014 Feb 19.

PMID:
24552678
[PubMed - indexed for MEDLINE]
10.

Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, Roth P, Lorincz AT, Gafni A.

CMAJ. 2000 Sep 19;163(6):701-7.

PMID:
11022584
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.

Vaccine. 2014 Feb 3;32(6):733-9. doi: 10.1016/j.vaccine.2013.11.049. Epub 2013 Nov 26.

PMID:
24291200
[PubMed - indexed for MEDLINE]
Free Article
12.

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.

Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.

PMID:
17117182
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The impact of the distribution of human papillomavirus types and associated high-risk lesions in a colposcopy population for monitoring vaccine efficacy.

Antonishyn NA, Horsman GB, Kelln RA, Saggar J, Severini A.

Arch Pathol Lab Med. 2008 Jan;132(1):54-60. doi: 10.1043/1543-2165(2008)132[54:TIOTDO]2.0.CO;2.

PMID:
18181674
[PubMed - indexed for MEDLINE]
14.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

PMID:
20647284
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Human papillomavirus genotype distribution in Madrid and correlation with cytological data.

Martín P, Kilany L, García D, López-García AM, Martín-Azaña MJ, Abraira V, Bellas C.

BMC Infect Dis. 2011 Nov 15;11:316. doi: 10.1186/1471-2334-11-316.

PMID:
22081930
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cervicovaginal smear abnormalities in sexually active adolescents. Implications for management.

Simsir A, Brooks S, Cochran L, Bourquin P, Ioffe OB.

Acta Cytol. 2002 Mar-Apr;46(2):271-6.

PMID:
11917572
[PubMed - indexed for MEDLINE]
17.

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.

Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL.

J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43.

PMID:
12953088
[PubMed - indexed for MEDLINE]
Free Article
18.

Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).

Orlando G, Tanzi E, Chatenoud L, Gramegna M, Rizzardini G; VALHIDATE Study Group.

BMC Cancer. 2012 May 30;12:204. doi: 10.1186/1471-2407-12-204.

PMID:
22646512
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark.

Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T.

Int J Cancer. 2008 Oct 15;123(8):1864-70. doi: 10.1002/ijc.23712.

PMID:
18661520
[PubMed - indexed for MEDLINE]
20.

Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.

Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M; VALGENT Study Group.

J Clin Microbiol. 2013 May;51(5):1458-64. doi: 10.1128/JCM.00087-13. Epub 2013 Feb 27.

PMID:
23447632
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk